Melanoma is the most lethal skin cancer, with increasing incidence rates.
The Brazilian National Cancer Institute (Instituto Nacional de Câncer - INCA) estimated the total incidence rate of cutaneous melanoma at 4.03 per 100,000 men and at 3.94 per 100,000 women in 2020. The highest incidence rates are found in the South region, with 6.49/100,000 men and 6.61/100,000 women. In addition, Santa Catarina is the state with the highest adjusted incidence of cutaneous melanoma in the country. Specifically, its capital Florianópolis presents the highest rates, with 14.82 cases per 100,000 in men and 12.22 cases per 100,000 in women.
Many risk factors for melanoma have been established, such as exposure to ultraviolet (UV) radiation; Fitzpatrick skin types I and II (skin that easily burns and does not tan or tans with difficulty, respectively);
The population of Santa Catarina, a state mainly composed of white-skinned inhabitants (83.97%),
The ABCDE rule is a useful tool for the investigation of suspected cutaneous melanoma.
The treatment options for melanoma are based on current knowledge of tumor biology and are chosen according to the individualized clinical assessment and to the disease stage. It is important to note that chemotherapy was the standard treatment for the metastatic disease until 2010. During this period, the use of alpha interferon as adjuvant therapy in early-stage diseases was questionable, with high toxicity as a limiting factor.
For adjuvant treatment, the available options are immunotherapy and targeted drugs. In addition to immunotherapy and target therapy for metastatic melanoma, the patient can be treated with chemotherapy and radiotherapy.
The Oncological Research Center (CEPON) is the reference public service in the macro-region of Florianopolis/Santa Catarina for oncological treatment. During the study period, it was the state reference for melanoma among the entire state of Santa Catarina, being the only center that performed sentinel lymph node biopsy. CEPON is involved in clinical research throughout the country, allowing patients in the public system access to various treatment modalities not yet included in the therapeutic arsenal of the Brazilian unified health system.
In this sense, it is essential to identify the clinical and sociodemographic profile of patients with cutaneous melanoma, considering the high exposure to risk factors for the disease and the incidence in the state of Santa Catarina and its capital city. Thus, this study aims at characterizing the clinical and sociodemographic profile of patients with cutaneous melanoma treated at a public oncology referral hospital in Florianópolis from January 2013 to December 2017.
This is a cross-sectional and descriptive study carried out at the Santa Catarina Oncological Research Center (CEPON), located in Florianópolis, Santa Catarina. The institution plays an important role in cancer treatment in the mesoregion of Florianópolis, is a referral hospital for melanoma treatment in the State of Santa Catarina (until 2018), and a reference for palliative medicine, according to the World Health Organization (WHO). The study included patients diagnosed with melanoma skin cancer (ICD-O, 3rd edition C44 - skin melanoma) treated at CEPON between January 2013 and December 2017. The sociodemographic information was obtained from the CEPON's Hospital Cancer Registry (HCR) database, whereas the clinical characteristics and treatments were verified by accessing electronic and physical medical records.
The following variables were considered in the study: sociodemographic variables (gender, age, ethnicity, schooling, working outdoors during sun exposure, and origin according to state region); treatment variables (first treatment received at the hospital); and clinical characteristics (histological type, primary tumor location, Breslow index, presence of ulceration in the primary tumor, tumor staging, presence of metastasis, and metastasis sites).
The data were inserted in a Windows Excel spreadsheet and analyzed using the Statistical Package for the Social Sciences (SPSS) program, version 18.0 (Chicago, SPSS Inc., U.S., 2009). The qualitative data were presented as simple and relative frequencies and the quantitative data as mean and standard deviation (SD).
This research was conducted according to Resolution No. 466/2012 of the National Health Council, approved by the Research Ethics Committees of the University of Southern Santa Catarina and of CEPON under CAAE registration numbers 26476019.0.3002.5355 and 26476019.0.0000.5369. The researchers declare no conflicts of interest.
The total number of cutaneous melanoma cases per year is shown in
| Year | n | % |
|---|---|---|
| 2013 | 68 | 14.53 |
| 2014 | 90 | 19.23 |
| 2015 | 100 | 21.37 |
| 2016 | 104 | 22.22 |
| 2017 | 106 | 22.65 |
The sociodemographic characteristics of the evaluated subjects are shown in
| Variables | n | (%) |
|---|---|---|
| Gender (n=468) Female | 239 | 51.07 |
| Male | 229 | 48.93 |
| Age (n=468) 11 to 20 | 1 | 0.21 |
| 21 to 30 | 24 | 5.13 |
| 31 to 40 | 71 | 15.17 |
| 41 to 50 | 89 | 19.02 |
| 51 to 60 | 106 | 22.65 |
| 61 to 70 | 113 | 24.15 |
| 71 to 80 | 49 | 10.47 |
| 81 to 90 | 15 | 3.2 |
| Race (n=468) Yellow | 2 | 0.43 |
| White | 458 | 97.87 |
| Brown | 4 | 0.85 |
| Black | 4 | 0.85 |
| Education (n=436) None 17 3.9 Incomplete primary education | 170 | 39.0 |
| Primary education | 72 | 16.51 |
| High school education | 99 | 22.7 |
| Incomplete undergraduate education | 16 | 3.67 |
| Undergraduate education | 62 | 14.22 |
| Working outdoor (sun exposure)(n=425) Yes | 152 | 35.76 |
| No | 273 | 64.24 |
| Origin (State region) (n=457) Greater Florianópolis | 340 | 74.5 |
| North | 5 | 1.0 |
| West | 28 | 6.1 |
| Mountain region (“Serra”) | 9 | 2.0 |
| South | 30 | 6.6 |
| Itajái Valley | 43 | 9.4 |
| Other States | 2 | 0.4 |
The most prevalent topographies of primary tumors are shown in
| Male | Female | |||
|---|---|---|---|---|
| Primary tumor location | n | % | n | % |
| Face | 19 | 8.3 | 13 | 5.44 |
| Scalp and neck | 23 | 10.04 | 14 | 5.86 |
| Trunk | 101 | 44.11 | 83 | 34.72 |
| Upper limb | 32 | 13.97 | 51 | 21.34 |
| Lower limb | 21 | 9.17 | 57 | 23.85 |
| Not specified | 33 | 14.41 | 21 | 8.79 |
Regarding the histological classification, 35.68% of the tumors were melanoma or melanoma NOS (no other specifications). In addition, the most frequent histological subtypes were superficial spreading (35.26%), followed by nodular melanoma (20.51%). Furthermore, 35.8% of the lesions in primary tumors presented ulceration.
The Breslow index and clinical-pathological staging were grouped according to the 8th edition of the AJCC.
| Variables | n | % |
|---|---|---|
| Histology (n = 468) Melanoma (no other specifications) | 167 | 35.68 |
| Superficial spreading | 165 | 35.26 |
| Nodular | 96 | 20.51 |
| Malignant lentigo | 12 | 2.56 |
| Acral | 18 | 3.85 |
| Other | 10 | 2.14 |
| Breslow (n = 468) Tis 53 11.33 <0.8mm | 73 | 15.60 |
| 0.8-1mm | 36 | 7.69 |
| >1-2mm | 84 | 17.95 |
| >2-4mm | 65 | 13.89 |
| >4mm | 61 | 13.03 |
| No information | 96 | 20.51 |
| Staging (n = 419) 0 53 12.65 IA | 56 | 13.37 |
| IB | 72 | 17.18 |
| IIA | 38 | 9.07 |
| IIB | 20 | 4.77 |
| IIC | 17 | 4.06 |
| IIIA | 10 | 2.39 |
| IIIB | 10 | 2.39 |
| IIIC | 22 | 5.25 |
| IIID | 4 | 0.95 |
| IV | 117 | 27.92 |
| Metastasis site (n = 117) | 43 | 19.64 |
| Non-regional lymph nodes | 38 | 17.35 |
| Bones | 18 | 8.22 |
| Central nervous system | 30 | 13.70 |
| Subcutaneous tissue | 14 | 6.39 |
| Liver | 20 | 9.13 |
| Adrenal | 8 | 3.65 |
| Skin | 7 | 3.20 |
| Peritoneum/retroperitoneum | 11 | 5.02 |
| Other | 20 | 13.70 |
Technical note:
79 of these (82.3%) presented evidence of metastasis;
57 of these (48.72%) had more than one site of metastasis.
Regarding the first treatment, 41.67% of the patients received only one modality at the first moment, 39.1% underwent more than one modality and 19.23% were not subjected to any treatment (16.67% due to follow-up loss).
Margin enlargement surgery was performed in 58.49% of the patients in CS 0, standing out among the indicated treatments. However, it is important to note that another 32.08% of the patients directly initiated clinical follow-up as they were operated on in other institutions.
Margin enlargement surgery was also the most frequent treatment for patients with CS IA (80.36%). However, sentinel lymph node biopsy (SLB) was performed in 62.5% of the cases with CS IB in addition to enlargement surgery. One patient in this group was subjected to lymphadenectomy associated with margin enlargement surgery as initial treatment (1.39%).
The patients with CS IIA, IIB, and IIC who underwent enlargement surgery associated with SLB for initial treatment accounted for approximately 92.10%, 80%, and 82.35%, respectively. Two patients with CS IIC were subjected to lymphadenectomy (11.76%).
This initial therapeutic scenario was similar for patients with CS III. Enlargement surgery associated with SLB was the most used procedure for patients with CS IIIA, IIIB and IIIC (60%, 40%, and 40.9%, respectively). However, it is important to note that other treatments were also applied, especially lymphadenectomy, performed in 20% of the patients with CS IIIA, 30% of those with CS IIIB, 27.27% with CS IIIC and 25% with CS IIID. Adjuvant interferon was used in three patients (6.39%) with unspecified CS III. Radiotherapy was used in 13.64% of the patients with CS IIIC and 25% with CS IIID. Only one patient with CS IIIC received chemotherapy (4.54%).
Chemotherapy (dacarbazine alone or carboplatin associated with paclitaxel) was used in 29.06% of the cases with CS IV melanoma, with 3.42% of these being associated with radiotherapy. The second most used treatment for this group of patients was radiotherapy, used alone in 19.09% and in combination with other therapies in 5.98% of the subjects. Importantly, target therapy (vemurafenib) was the first choice for 8.55% of the cases.
In addition to these treatments, immunotherapy (nivolumab or pembrolizumab) was the therapy of choice for 5.13% of the patients. Direct referral to the palliative care team occurred in 6.84% of the cases. Other approaches were also indicated as first treatment, such as margin enlargement surgery associated with SLB (4.27%), metastasectomy (1.71%), lymphadenectomy (7.69%) and three patients (2.56%) underwent the trilogy (vemurafenib, cobimetinib associated with atezolizumab or placebo) research protocol. Finally, 20 patients with CS IV did not receive any treatment (17.09%). Among the reasons are follow-up loss, treatment options at another institution, and death before the scheduled treatment.
Cutaneous melanoma is a prevalent neoplasm in Santa Catarina, especially in Florianópolis, when compared with other Brazilian cities. In this sense, the current study was conducted at CEPON, the referral hospital for the treatment of melanoma in the state of Santa Catarina.
This research involved 468 patients, 239 women and 229 men, with a slight predominance of female cases with cutaneous melanoma. These findings corroborate with other publications in the area. In a study conducted in São Paulo by Melo et al. (2018),
Regarding age at diagnosis, 79.49% of the patients were over 40 years old, corroborating Paulson et al.,
The present study identified that 97.87% of the subjects with cutaneous melanoma were white-skinned, similar to studies carried out in the country by Wainstein et al. (2020)
It was observed that 3.9% of the patients had no schooling and 39% presented incomplete primary education. On the other hand, 57.1% had completed primary, high school, or undergraduate education. These data are similar to those found by the 2010 Brazilian National Demographic Census concerning the Santa Catarina population's schooling levels. According to the census, 32.07% had no school education or incomplete primary school, whereas 58.05% had finished primary school or more.
Sun exposure, mainly through intermittent exposure and sunburn, has a strong association with the development of melanoma. Despite this relationship, the present study identified only 35.76% of patients working under high sun exposure, a result similar to that observed by Ferreira et al. (2018),
Regarding tumor histology, spreading superficial melanoma was also the most frequent subtype observed in Brazilian studies, as reported by Wainstein et al. (2020)
The most frequent primary tumor site was located in the trunk in both genders (39.32%). It is possible to find divergent data in the literature regarding this variable. According to Lima et al. (2015)
The Breslow index was grouped as suggested by the 8th edition of the AJCC.
This result was different from other studies with a similar design, such as Lima et al. (2015),
Most diseases were staged at CS IV (27.92%) during diagnosis, characterized as metastatic and with a worse prognosis. Early diagnosis is considered difficult since the lesions are initially asymptomatic, delaying search for medical care. This result was also different from studies with a similar design in which CS IV was the least prevalent. According to Foiato et al. (2018),
The first treatment received at the hospital varied according to the patients' CS and was in accordance with the national recommendations.
These results can target primary and secondary prevention campaigns and policies for this population and reduce the high rate of metastatic disease diagnoses. In this sense, the present study highlights the increased prevalence of advanced melanoma and, thus, ratifies the need for improvement and access to better treatments in the public scenario. Therefore, we believe that the recent approval by the National Commission for the Incorporation of Technologies (Comissão Nacional de Incorporação de Tecnologias, CONITEC) in the unified health system of immunotherapy for advanced non-surgical and metastatic melanoma, according to ordinance SCTIE/MS No. 23, dated August 4th, 2020, will be a game-changer in this scenario.
The descriptive, cross-sectional and observational design has some limitations and biases. Selection bias may have occurred since only patients referred to the institution are treated. Many may not have been referred in the case of diseases with early diagnosis, underestimating the number of melanoma cases. It is also important to highlight the absence of some information in the database of this study. To minimize this bias, it was necessary to resort to physical medical records, although few relevant data have been found, representing a problem inherent to retrospective studies. In this same sense, the situation worsened with restricted access to the Institution due to the COVID-19 pandemic.
Thus, the sociodemographic data and the topography of the injuries could not be reviewed according to the medical records. Another limitation was related to the pathological skin analysis carried out by professionals from different institutions who, in some cases and for unknown reasons, did not describe the histological subtype in their reports, making it difficult to standardize the information.
In summary, it is concluded that the sociodemographic profile and the clinical characteristics (e.g., location of the primary tumor, histological subtype) were similar to those obtained by other national and international studies.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Journal: Brazilian Journal of Oncology
DOI: 10.1055/s-00059887
e-issn: 2526-8732
Publisher: Thieme Revinter Publicações Ltda.
Publisher address: Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
No citations found for this article.
1. American Cancer Society (ACS). Cancer facts & figures 2019. ACS, 2019.
2. Siegel, RL and Miller, KD and Jemal, A. Cancer statistics, 2019. CA Cancer J Clin [online]. 2019, vol. 69, p. 7-34.
3. Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Estimativa 2020: incidência de câncer no Brasil [Internet]. INCA, 2019.
4. Fitzpatrick, TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol [online]. 1988, vol. 124, p. 869-871.
5. O'Neill, CH and Scoggins, CR. Melanoma. J Surg Oncol [online]. 2019, vol. 120, p. 873-881.
6. Alexandrov, LB and Nik-Zainal, S and Wedge, DC and Aparicio, SAJR and Behjati, S and Biankin, AV. Signatures of mutational processes in human cancer. Nature [online]. 2013, vol. 500, p. 415-421.
7. Hodis, E and Watson, IR and Kryukov, GV and Arold, ST and Imielinski, M and Theurillat, JP. A landscape of driver mutations in melanoma. Cell [online]. 2012, vol. 150, p. 251-263.
8. Berger, MF and Hodis, E and Heffernan, TP and Deribe, YL and Lawrence, MS and Protopopov, A. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature [online]. 2012, vol. 485, p. 502-506.
9. Parkin, DM and Mesher, D and Sasieni, P. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010. Br J Cancer [online]. 2011, vol. 105, p. S66-S69.
10. Instituto Brasileiro de Geografia e Estatística (IBGE). Censo demográfico 2020 [Internet]. IBGE, 2020.
11. Naser, N. Melanoma cutâneo: estudo epidemiológico de 30 anos em cidade do sul do Brasil, de 19802009. An Bras Dermatol [online]. 2011, vol. 86, p. 932-941.
12. Lima, AS and Stein, CE and Casemiro, KP. Epidemiology of melanoma in the South of Brazil: study of a city in the Vale do Itajaí from 1999 to 2013. An Bras Dermatol [online]. 2015, vol. 90, p. 185-189.
13. Dimatos, DC and Duarte, FO and Vieira, VJ and Vasconcellos, ZAZ and Bins-Ely, J and Neves, RD. Melanoma cutâneo no Brasil. Arq Catarin Med [online]. 2009, vol. 38, p. 14-19.
14. Battisti, R and Nunes, DH and Weber, AL and Schweitzer, LC and Sgrott, I. Avaliação do perfil epidemiológico e da mortalidade dos pacientes com diagnóstico de melanoma cutâneo primário no município de Florianópolis - SC, Brasil. An Bras Dermatol [online]. 2009, vol. 84, p. 335-342.
15. Breslow, A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg [online]. 1970, vol. 172, p. 902-908.
16. Amin, MB and Edge, SB and Greene, FL and Byrd, DR and Brookland, RK and Washington, MK. AJCC cancer staging manual. Springer;, 2017.
17. Mocellin, S and Pasquali, S and Rossi, CR and Nitti, D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst [online]. 2010, vol. 102, p. 493-501.
18. Robert, C and Karaszewska, B and Schachter, J and Rutkowski, P and Mackiewicz, A and Stroiakovski, D. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med [online]. 2015, vol. 372, p. 30-39.
19. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell [online]. 2015, vol. 161, p. 1681-1696.
20. National Comprehensive Cancer Network (NCCN). Guideline for patients - melanoma [Internet]. NCCN, 2021.
21. Melo, AC and Wainstein, AJA and Buzaid, AC and Thuler, LCS. Melanoma signature in Brazil: epidemiology, incidence, mortality, and trend lessons from a continental mixed population country in the past 15 years. Melanoma Res [online]. 2018, vol. 28, p. 629-636.
22. Wainstein, AJA and Neto, JPD and Enokihara, MY. Demographic, clinical, and pathologic features of patients with cutaneous melanoma: final analysis of the Brazilian Melanoma Group Database. JCO Glob Oncol [online]. 2020, vol. 6, p. 575-582.
23. Foiato, TF and Bereza, BRK and Montenegro, MF and Guilherme, MR and Volski, LB and Rebolho, JC. Analysis of patients diagnosed with primary cutaneous melanoma in the last six years in Hospital Erasto Gaertner: epidemiologic profile. An Bras Dermatol [online]. 2018, vol. 93, p. 332-336.
24. Paulson, KG and Gupta, D and Kim, TS and Veatch, JR and Byrd, DR and Bhatia, S. Age-specific incidence of melanoma in the United States. JAMA Dermatol [online]. 2020, vol. 156, p. 57-64.
25. Ferreira, T and Santos, IDAO and Oliveira, AF and Ferreira, LM. Estudo retrospectivo dos pacientes portadores de melanoma cutâneo atendidos na Universidade Federal de São Paulo. Rev Col Bras Cir [online]. 2018, vol. 45, p. e1715.
26. Costa, LMM and Crovador, CS and Carvalho, CEB and Vazquez, VL. Characteristics of Brazilian melanomas: real-world results before and after the introduction of new therapies. BMC Res Notes [online]. 2019, vol. 12, p. 296.
27. Olsen, CM and Pandeya, N and Thompson, BS and Dusingize, JC and Green, AC and Neale, RE. Association between phenotypic characteristics and melanoma in a large prospective cohort study. J Invest Dermatol [online]. 2019, vol. 139, p. 665-672.
28. Perera, E and Gnaneswaran, N and Jennens, R and Sinclair, R. Malignant melanoma. Healthcare (Basel) [online]. 2013, vol. 2, p. 1-19.
29. Vazquez, VL and Silva, TB and Vieira, MA and Oliveira, ATT and Lisboa, MV and Andrade, DAP. Melanoma characteristics in Brazil: demographics, treatment, and survival analysis. BMC Res Notes [online]. 2015, vol. 8, p. 4.
30. Tomizuka, T and Namikawa, K and Higashi, T. Characteristics of melanoma in Japan: a nationwide registry analysis 2011-2013. Melanoma Res [online]. 2017, vol. 27, p. 492-497.
31. Loria, D and Abriata, MG and Santoro, F and Latorre, C. Cutaneous melanoma in Argentina: an analysis of its characteristics and regional diferences. Ecancer [online]. 2020, vol. 14, p. 1017.
32. Eggermont, AMM and Blank, CU and Mandala, M and Long, GV and Atkinson, V and Dalle, S. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med [online]. 2018, vol. 378, p. 1789-1801.
33. Eggermont, AM and Chiarion-Sileni, V and Grob, JJ and Dummer, R and Wokchok, JD and Schmidt, H. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol [online]. 2015, vol. 16, p. 522-530.
34. Weber, J and Mandala, M and Del Vecchio, M and Gogas, HJ and Arance, AM and Cowey, L. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med [online]. 2017, vol. 377, p. 1824-1835.
Dados de acesso insuficientes para visualização no mapa.